There are many reasons why doctors may choose FASLODEX. Understanding how estrogen affects
breast cancer and how FASLODEX may work can help you evaluate FASLODEX and
help you understand your doctor’s decision.
Estrogen plays an important role
Hormone receptor-positive metastatic breast cancer often relies on estrogen to grow and progress.
When the supply of estrogen is reduced or blocked, breast cancer cells may not multiply
or grow as quickly. Here’s a simple way to think about how FASLODEX interacts with
hormone receptors to limit cancer cell growth.
FASLODEX targets the estrogen receptor
- FASLODEX binds to estrogen receptors and blocks the effect estrogen has on the
- FASLODEX causes the estrogen receptor to change shape and not work as well
- FASLODEX decreases the number of estrogen receptors, so there are fewer receptors
available for the estrogen to act on
Continuing on hormonal therapy
If you have metastatic breast cancer that responded to antiestrogen therapy in the past, and you have recently experienced
disease progression (your disease has spread), FASLODEX may be an option for you. FASLODEX has been proven effective in treating postmenopausal women with hormone receptor-positive metastatic breast cancer after previous
antiestrogen therapy has failed.
FASLODEX has been prescribed for over 10 years. Talk to your doctor to see if FASLODEX is an appropriate
option for you.
Established safety profile
For over a decade, doctors have counted on FASLODEX to increase the period of progression-free survival
and to provide an established safety profile. Understandably,
finding a treatment that balances safety and efficacy is often a priority for patients.
Talk to your doctor about how you are feeling and ask about the potential benefits
and risks associated with any medications.
In a large clinical trial studying both efficacy and safety, the 500-mg dose of
FASLODEX showed comparable safety to FASLODEX 250 mg. Fewer than 1% of patients stopped taking either FASLODEX
500 mg or 250 mg because of FASLODEX-related side effects. Because FASLODEX is
metabolized, or broken down primarily in the liver, a monthly dose of 250 mg is
recommended for patients with moderate liver problems. FASLODEX was not studied in
patients with severe liver problems.
Read about how FASLODEX may be able
to help you